- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07809100
Tumoral Versus Luminal Microbiome in Head and Neck Squamous Cell Carcinoma (MIC-VADS)
Head and neck squamous cell carcinoma (HNSCC), France's 5th most common cancer (15,000 annual cases), presents significant public health challenges due to high morbidity and functional/aesthetic sequelae from treatments (mutilating surgery, radiotherapy, chemotherapy). Major risk factors, tobacco and alcohol, create a chronic inflammatory environment promoting tumor development. The upper aerodigestive tract microbiome, influenced by these exposures and local alterations (necrosis, bleeding, ulcerations), is emerging as a potential factor in tumor progression, severity biomarker, or therapeutic target, though its exact role (cause or consequence) remains to be elucidated
Objectives:
- Primary: Compare bacterial microbiome composition between tumor tissue, adjacent healthy mucosa, and pharyngeal secretions
- Secondary:
- Correlate microbiome diversity/composition with clinical and epidemiological characteristics
- Identify microbiome variations by tumor stage, histology, and infiltration
- Discover diagnostic/prognostic microbial markers
- Analyze somatic variants (SNP/CNV) via whole-genome sequencing (WGS) and their association with microbiome profiles and clinical parameters
Study Design: Prospective, cross-sectional study with paired design (each patient serves as their own control to minimize genetic variation biases)
Methods:
- Samples: Tumor, adjacent healthy tissue, and pharyngeal secretions (3 samples/patient)
- Sequencing: Metagenomic sequencing (complete bacterial genomes) when biomass permits, or targeted 16S rRNA sequencing to identify dominant genera.
- Pilot study: 20 patients to select the optimal technique and validate feasibility, particularly assessing DNA quantity in these low-biomass environments
Population: Adults with suspected HNSCC scheduled for panendoscopy
Exclusion criteria: Recent antibiotics/corticosteroids (12 weeks), immunosuppression (uncontrolled HIV, active hematologic malignancies, autoimmune diseases on immunosuppressants, organ/stem cell transplants, uncontrolled diabetes), immunomodulatory treatments (3 months), recurrence, pregnancy, non-French speakers, legal guardianship, or lack of social security.
Safety: No additional risks beyond standard panendoscopy.
Expected impact: This approach may pave the way for innovative diagnostic or therapeutic strategies based on microbiome modulation in HNSCC.
Studie Overzicht
Toestand
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Caroline TOURTE
- Telefoonnummer: +33 01 61 69 31 50
- E-mail: caroline.tourte@chsf.fr
Studie Contact Back-up
- Naam: Renato TORRES, MD
- Telefoonnummer: +33 01 61 69 34 59
- E-mail: renato.torres-lazo@chsf.fr
Studie Locaties
-
-
France
-
Corbeil-Essonnes, France, Frankrijk, 91100
- Centre Hospitalier Sud Francilien
-
Contact:
- Renato TORRES, MD
- Telefoonnummer: +33 01 61 69 34 59
- E-mail: renato.torres-lazo@chsf.fr
-
Hoofdonderzoeker:
- Renato TORRES, MD
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Adult patient
- Consultation in the ENT department for suspected squamous cell carcinoma of the upper aerodigestive tract scheduled for panendoscopy
- Patient has provided consent to participate in the study and signed an informed consent form
Exclusion Criteria:
-
Antibiotic or corticosteroid therapy within 12 weeks prior to consultation
-
Conditions associated with immunosuppression:
- Uncontrolled HIV infection (CD4 < 200 cells/µL) (permanent exclusion)
- Hematologic malignancies currently under treatment or not in complete remission for <2 years
- Autoimmune diseases under immunosuppressive treatment
- Solid organ or stem cell transplant recipients (permanent exclusion)
- Poorly controlled diabetes (HbA1c > 9%)
-
Immunomodulatory treatment within 3 months prior to consultation:
- Immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1, anti-CTLA-4)
- Biotherapy targeting the immune system (anti-TNF, anti-IL, calcineurin inhibitors, antimetabolites)
- Recurrent upper aerodigestive tract cancer previously treated with surgery and/or radiochemotherapy
- Pregnancy (confirmed prior to panendoscopy)
- Patient who does not speak or understand French
- Subject under guardianship or curatorship
- Subject not affiliated with the national health insurance system
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Fundamentele wetenschap
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Microbiome in head and neck squamous cell carcinoma Patients
Patients with suspected head and neck squamous cell carcinoma undergoing panendoscopy with additional biopsy sampling of tumor tissue, adjacent healthy mucosa, and pharyngeal secretions for microbiome analysis |
Additional biopsies (beyond standard clinical practice) taken during panendoscopy to collect:
These samples are used for microbiome analysis. head and neck squamous cell carcinoma Note: The panendoscopy itself is a standard clinical procedure, but the additional biopsies for research purposes represent the study-specific intervention. Additional biopsies (beyond standard clinical practice) taken during panendoscopy to collect:
These samples are used for microbiome analysis. head and neck squamous cell carcinoma Note: The panendoscopy itself is a standard clinical procedure, but the additional biopsies for research purposes represent the study-specific intervention. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
The difference in bacterial composition between the tumor, healthy mucosa, and hypopharyngeal secretions will be assessed
Tijdsspanne: at day 1
|
at day 1
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Differences in the tumor microbiome between subgroups defined by tumor stage, histological type, or infiltration, using differentiation tests
Tijdsspanne: at day 1
|
at day 1
|
|
|
Differential bacterial genera or strains between tumor, healthy, and pharyngeal microbiomes
Tijdsspanne: at day 1
|
at day 1
|
|
|
Correlations between tumor microbiome diversity and composition and clinical/epidemiological data
Tijdsspanne: at day 1
|
tumor microbiome diversity (by sequencing) tumor microbiome composition (by sequencing) |
at day 1
|
Medewerkers en onderzoekers
Onderzoekers
- Studie directeur: Béatrice SEGURENS, Phd, HDR
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 2026-A00392-49
- 2026/0003 (Andere identificatie: CHSF)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .